Patient death in Sophiris' prostate cancer trial deemed unrelated to topsalysin

Sophiris Bio Inc. (NASDAQ:SPHS) said that the patient death reported in June from a Phase IIb trial evaluating topsalysin (PRX302) to treat localized prostate cancer is unlikely to be related to either topsalysin or the administration procedure. The candidate is a recombinant proaerolysin protein activated by prostate-specific antigen (PSA; KLK3).

In June, the company said a patient death occurred on the same day the patient received a second intraprostatic administration of topsalysin in the open-label, U.S. and U.K. trial (see "Sophiris Reports Patient Death in Prostate Cancer Trial")...